Overview
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of Generalised Lipodystrophy
- Metreleptin treatment naive
Exclusion Criteria:
- Weight <9 kg at Screening (Visit 1)